Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study

References

• Lamb CA, Kennedy NA, Raine T, et al. IBD guidelines delphi consensus group. British society of gastroenterology consensus guidelines on managing inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60.
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burish J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2–17.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152:351–361.e355.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–608.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. UK inflammatory bowel disease pharmacogenetics study group. predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Glob Health. 2019;4:341–353
   Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.e1310.
   PubMed Web of Science ®Google Scholar
• McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883–898.
   PubMed Web of Science ®Google Scholar
• Lobaton T, Vermeire S, Van Assche G, et al. Review article: anti‐adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579‐594.
   PubMed Web of Science ®Google Scholar
• Vedolizumab -FDA. https://www.acces.sdata.fda.gov/drugs.atfda_docs/label/2020/125476s025.s030l.bl.pdf. Accessed August 22,2022
   Google Scholar
• Entyvio European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio. Accessed August 22,2022
   Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. GEMINI 1 study group. GEMINI 1 study group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. GEMINI 2 study group. GEMINI 2 study group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11:400–411.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Loftus EV, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohns Colitis. 2017;11:412–424.
   PubMed Web of Science ®Google Scholar
• Danese S, Subramaniam K, Van Zyl J, et al. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther. 2021;53:265–272.
   PubMed Web of Science ®Google Scholar
• Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002–1007.
   PubMed Web of Science ®Google Scholar
• Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis. 2018;12:245–257.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048–1064.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the Cross Pennine study. Dig Liver Dis. 2018;50:1299–1304.
   PubMedGoogle Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111:1147–1155.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Faggiani R, et al. Vedolizumab is effective and safe in in real-life treatment of inflammatory bowel diseases outpatients: a multicenter, observational study in primary inflammatory bowel disease centers. Eur J Intern Med. 2019;66:85–91.
   PubMed Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113:1345.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Verstockt B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naive patients with inflammatory bowel disease-a multicenter retrospective European study. Inflamm Bowel Dis. 2018;24:2442–2451.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet, et al. OBSERV-IBD study group, the GETAID. Three year effectiveness and safety of Vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50:40–53.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Ricart E, et al. GETECCU study group. The short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018;48:839–851.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Privitera G, Crispino F, et al. IG‐IBD LIVE Study Group. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56:95–109.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Avni-Biron I, Ron Y, et al. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real-world experience. Dig Liver Dis. 2019;51:68–74.
   PubMedGoogle Scholar
• Kopylov U, Verstockt B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naive patients with inflammatory bowel disease-a multicenter retrospective European study. Inflamm Bowel Dis. 2018;24:2442–2451.
   PubMed Web of Science ®Google Scholar
• Bressler B, Yarur A, Silverberg M, et al. Vedolizumab and anti-tumour necrosis factor alfa real-world outcomes in biologic-naive Inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15:1694–1706.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Crohns Colitis. 2017;11:649–670.
   Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113:481–517.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med. 1987;317:1625–1629.
   PubMed Web of Science ®Google Scholar
• Best WR. Predicting the Crohn’s Disease activity index from the Harvey–Bradshaw Index. Inflamm Bowel Dis. 2006;12:304–310.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
   PubMed Web of Science ®Google Scholar
• Moskovitz DN, Daperno M, Van Assche G. Defining and validating cut-offs for the simple endoscopic score for Crohn’s disease. Gastroenterology. 2007;132:S1097.
   Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambroun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15–29.
   PubMed Web of Science ®Google Scholar
• Samaan MA, Pavlidis P, Johnston E, et al. vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8:196–202.
   PubMed Web of Science ®Google Scholar
• Barre A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:896–905.
   PubMed Web of Science ®Google Scholar
• Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut. 2019;68:814–828.
   PubMed Web of Science ®Google Scholar
• Biemans VB, Van Der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123–134.
   PubMed Web of Science ®Google Scholar
• Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;52:1341–1352.
   PubMed Web of Science ®Google Scholar
• Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51:948–957.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Cuomo A, et al. Real-life efficacy and safety of ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study. Eur Rev Med Pharmacol Sci. 2021;25:2099–2108.
   PubMed Web of Science ®Google Scholar
• Domenis R, Marino M, Cifù A, et al. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to vedolizumab. PLoS One. 2020;15:e0242342.
   PubMed Web of Science ®Google Scholar
• Dai C, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: current evidence and perspectives. Int Immunopharmacol. 2023;114:109545.
   PubMedGoogle Scholar
• Rozich JJ, Holmer A, Singh S. Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases. Am J Gastroenterol. 2020;115:832–840.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Zhang X, Brenner EJ, et al. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. J Crohns Colitis. 2021;15:1877–1884.
   PubMedGoogle Scholar
• Papa A, Scaldaferri F, Covino M, et al. Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: a Case-Control Study. Biomedicines. 2022;10:843.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Ferretti F, Monico MC, et al. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. J Gastroenterol Hepatol. 2021;36:3050–3055.
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725–732.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930–942.
   PubMed Web of Science ®Google Scholar
• Neurath MFCOVID-19. and immunomodulation in IBD. Gut. 2020;69:1335–1342.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Sarzi-Puttini PC, Preventing AS. COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2020;2:e255–6.
   PubMedGoogle Scholar